Zoetis Inc. ZTS 95.6
Health Care · NYSE · Data as of 2026-08-06
Zoetis Inc. (ZTS) has delivered +8.0% annualized revenue growth, +14.1% earnings growth, and +20.5% dividend growth over 10 years of data. Ranked #2 of 1968 stocks overall and #1 of 260 in the Health Care sector by Steady Score.
About Zoetis Inc.
Company Overview
Zoetis develops and supplies veterinary medicines, vaccines and diagnostic products for pets and livestock. Its customers include veterinary practices and animal producers, whose needs range from routine prevention to treating disease and monitoring animal health. The portfolio covers companion animals such as dogs and cats as well as farmed species, bringing together treatments, testing tools and related services across different stages of animal care.
Read more
Business Model & Revenue
Zoetis sells animal health products through direct sales teams and distribution partners. Revenue includes medicines used repeatedly in preventive care or chronic treatment, together with vaccines, diagnostic instruments and testing supplies. Research supports new products, while established brands can gain additional uses, formulations or geographic approvals. Sales depend on veterinary prescribing, product adoption and spending by pet owners and livestock producers.
Key Facts & Market Position
Brands include Apoquel and Cytopoint for canine dermatology, Simparica for parasite control, and Librela and Solensia for osteoarthritis pain. This mix spans pharmaceuticals, biological treatments and diagnostics. Zoetis operates in both pet care and livestock health, giving it exposure to clinical treatment decisions and the economics of animal production.